Study S002449

Does Urinary C-peptide Creatinine Ratio Predict Response to Incretin Based Agents in Type 2 Diabetes

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT01503112
Acronym: PRIBA
Study type: OBSERVATIONAL
Status: COMPLETED
Enrollment: 957
Start: 2011-05
Primary completion: 2014-04
Lead sponsor: Royal Devon and Exeter NHS Foundation Trust
Conditions: Type2 Diabetes
Interventions: OTHER:No intervention, observational study
Results posted: FALSE

Registered primary outcomes

Glycaemic response (HbA1c change post treatment) [6 months]

Linked records (3)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0024937	Precision Medicine in Type 2 Diabetes: Clinical Markers of Insulin Resistance Are Associated With Altered Short- and Long-term Glycemic Response to DPP-4 Inhibitor Therapy. Dennis JM, Diabetes care	2018	Other	PMID 29386249 DOI	cites ClinicalTrials.gov:NCT01503112; registry reference RESULT:29386249
R0017545	Markers of β-Cell Failure Predict Poor Glycemic Response to GLP-1 Receptor Agonist Therapy in Type 2 Diabetes. Jones AG, Diabetes care	2016	Other	PMID 26242184 DOI	cites ClinicalTrials.gov:NCT01503112; registry reference RESULT:26242184
R0027655	Identifying good responders to glucose lowering therapy in type 2 diabetes: implications for stratified medicine. Jones AG, PloS one	2014	Nonrandomized study	PMID 25340784 DOI	cites ClinicalTrials.gov:NCT01503112; registry reference RESULT:25340784